Indication: Type 2 Diabetes (T2D)
Efficacy and safety of oral semaglutide versus placebo both in combination with metformin and/or basal insulin in children and adolescents with type 2 diabetes
Sub-indication: Type 2 Diabetes (T2D)
Principal Investigator: Kupper Wintergerst, M.D.Norton Children's Endocrinology, affiliated with the UofL School of Medicine
Sponsor: Novo Nordisk, Inc.